乙型肝炎病毒BCP变异与拉米夫定治疗后HBVDNA反弹关系的研究

苏明华; 江建宁; 周元平; 陈茂伟; 刘志红

乙型肝炎病毒BCP变异与拉米夫定治疗后HBVDNA反弹关系的研究

1. 广西医科大学第一附属医院感染性疾病科
2. 广州南方医院

基金项目:

广西自然科学基金项目(桂科0342009)；

详细信息

中图分类号: R512.6
计量
- 文章访问数: 2253
- HTML全文浏览量: 30
- PDF下载量: 839
- 被引次数: 0
出版历程
- 出版日期: 2008-03-20

Study of the relationship between BCP mutation in the hepatitis B virus gene and HBVDNA rebound after lamivudine therapy

Research funding:

摘要

摘要: 目的探讨HBV BCP变异与拉米夫定抗病毒治疗后HBVDNA反弹的关系。方法应用PCR-序列分析法,检测拉米夫定治疗（100mg/d）1年以上,达到病毒学应答半年以上,再出现HBV DNA反弹（HBV DNA拷贝数≥1.0×104拷贝/ml）的27例乙型肝炎患者（治疗组）,以及19例从未用过抗病毒治疗患者（对照组）的HBV C区基本核心启动子（BCP）的突变位点。结果1.治疗组HBVDNA反弹的27例BCP（A1762T+G1764A）变异检出率44.44%（12/27）高于对照组26.32%（5/19）,但无统计学差异,P>0.05。2.4例HBVDNA反弹患者治疗前未检出BCP（A1762T+G1764A）变异,治疗后有2例检出BCP（A1762T+G1764A）变异。结论BCP（T1762/A1764）变异可能与拉米夫定治疗后HBVDNA反弹有关。
- 乙型肝炎病毒 /
- 基本核心启动子变异 /
- 拉米夫定 /
- HBVDNA反弹
Abstract: Objective To investigate the relationship of Hepatitis B virus BCP mutation in the hepatitis B virus (HBV) genome and HBVDNA rebound after with lamivudine therapy.Methods With inspected twenty-seven patients (therapy group, HBVDNA>104 copie4/ml) with HBVDNA rebound after respond to virus beyond 6 months with infecting hepatitis B received lamivudine (100mg/day) oral application for at least 12 months and nineteen patients (control group) with infecting hepatitis B without treated with the drug of antivirus, we have examined mutation in the Basal Core Promoter (BCP) of the Hepatitis B virus (HBV) of two group by PCR-gene sequence analysis.Results 1.The rate of BCP (A1762T+G1764A) mutations were 44.44% (12/27) in HBVDNA-negative group beyond control group 6.32% (5/19) , but it has not statistic difference (P>0.05) .2.In the therapy group, BCP (A1762T+G1764A) mutation were not examined in four patients before therapy, but it were examined in two patients after therapy.Conclusion BCP (T1762/A1764) mutation may be associated with HBVDNA rebound after lamivudine therapy.
- hepatitis B virus /
- BCP mutation /
- Lamivudine /
- HBV DNA rebound

HTML全文

参考文献(8)

[1] 中华医学会.病毒性肝炎防治方案[J].中西医结合肝病杂志, 2001, 11 (1) ∶56-60.

[2]Liaw YF, Leung NW, Chang TT, et al.Effects of extended lamivu-dine therapy in Asian patients with chronic hepatitis B[J].Gastroen-terology, 2000, 119 (1) ∶172-180.

[3]Leung NW, Lai CL, Chang LR, et al.Extended lamivudine treat-ment in patients with chronic hepatitis B enhances hepatitis B e anti-gen seroconversion rates:results after3 years of therapy[J].Hepatol-ogy, 2001, 33 (6) ∶1527-1532.

[4]Lok AS, McMahon BJ.Chronic hepatitis B:Update of Recommenda-tions[J].Hepatology, 2004, 39 (3) ∶857-861.

[5]Stuyver LJ, Locarnini SA, Lok A, et al.Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase re-gion[J].Hepatology, 2001, 33 (3) ∶751-757.

[6]Laras A, Koskinas J, Hadziyannaia SJ.In vivo suppression of pre-core mRNA synthesis is associated with mutations in the hepatitis Bvirus core promoter[J].Virology, 2002, 30 (1) ∶86-96.

[7]Chen CH, Lee CM, Lu SN, et al.Comparison of sequence changesof precore and core promoter regions in HBeAg-positive chronichepatitis B patients with and without HBeAg clearance in lamivudinetherapy[J].J Hepatol, 2006, 44 (1) ∶76-82.

[8]Tacke F, Gehrke C, Luedde T, et al.Basal core promoter and pre-core mutations in the hepatitis B virus genome enhance replication ef-ficacy of Lamivudine-resistant mutants[J].J Virol, 2004, 78 (16) ∶8524-35.

施引文献

资源附件(0)

访问统计